Chemical industry – Page 100
-
Business
Dow makes $1.5bn divestiture plans
Liveris in favour of ‘selectively pruning’ further non-core units
-
Business
Dispute over Arkema finances
French speciality chemical company Arkema accused of misrepresenting business sold to investment firm last year
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe
-
Business
Alcohol dependence pill approved in EU
Selincro tablets from Lundbeck designed to reduce consumption of alcohol
-
Business
University to acquire Shell UK R&D site
Site at Thornton will become a science park under the stewardship of the University of Chester
-
BusinessUK considers patent rule change for trials
Government to change law that organisations say makes the country less appealing as a location for clinical trials
-
Business
Dow rapped for $1bn tax scheme
Judge opines: ‘tax law deals in economic realities, not legal abstractions’
-
Business
Does chemical regulation boost innovation?
Report suggests that supply of innovation responds to extra demand created by new laws
-
Business
Talk of a $6.6bn deal for Elan
Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights
-
Business
$595m octreotide deal grabs Roche
Company will get worldwide rights to oral formulation of growth hormone drug
-
Business
Merck resolves Vytorin case for $688m
Investors say the company knew about Enhance trial failure but withheld information
-
Business
BMS sells OTC drugs for $482m
Bristol-Myers Squibb will offload rights to a range of over-the-counter products to Reckitt Benckiser
-
CareersToxicologist with pesticides on the brain
Vanessa Fitsanakis’ career in toxicology goes all the way back to the farm where she grew up. Helen Carmichael traces her journey from agriculture to academia
-
Business
Biogen buys Tysabri from Elan for $3.25bn
Elan earns huge cash injection for blockbuster drug
-
News
Small business office chemical industry pawn, watchdog claims
The US Small Business Administration’s little-known Office of Advocacy is accused of trying to dilute efforts to regulate certain chemicals
-
Business
GSK commits to AllTrials data disclosure
Company will begin publishing all clinical study reports
-
BusinessReach reviewed: no change required
But disproportionate cost of compliance for small and medium size companies should be reduced, European commission says
-
BusinessEU proposes neonicotinoid pesticide ban
Clothianidin, thiamethoxam and imidacloprid at centre of debate over declining bee populations